Fortem Financial Group LLC Has $233,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Fortem Financial Group LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 25.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,423 shares of the company’s stock after selling 496 shares during the period. Fortem Financial Group LLC’s holdings in Johnson & Johnson were worth $233,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Red Wave Investments LLC grew its position in shares of Johnson & Johnson by 2.0% in the 2nd quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock valued at $530,000 after purchasing an additional 59 shares during the period. Argus Investors Counsel Inc. boosted its holdings in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock valued at $1,941,000 after buying an additional 61 shares during the last quarter. Alta Capital Management LLC raised its stake in Johnson & Johnson by 0.4% in the 2nd quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock valued at $2,808,000 after acquiring an additional 61 shares during the period. Paces Ferry Wealth Advisors LLC raised its stake in Johnson & Johnson by 0.7% in the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock valued at $1,425,000 after acquiring an additional 62 shares during the period. Finally, Mason & Associates Inc raised its stake in Johnson & Johnson by 4.9% in the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock valued at $215,000 after acquiring an additional 62 shares during the period. 67.94% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 0.3 %

Shares of NYSE:JNJ opened at $168.31 on Tuesday. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The business has a 50 day simple moving average of $176.07 and a two-hundred day simple moving average of $171.13. The firm has a market capitalization of $440.04 billion, a PE ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s payout ratio is presently 62.95%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent research reports. Sanford C. Bernstein lowered their price objective on Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Bank of America cut their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research note on Friday, October 14th. Atlantic Securities lowered their price objective on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Raymond James lowered their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. Finally, Morgan Stanley decreased their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $181.75.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, EVP Ashley Mcevoy sold 73,323 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total value of $12,865,986.81. Following the completion of the sale, the executive vice president now owns 41,813 shares in the company, valued at approximately $7,336,927.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Insiders have sold a total of 233,611 shares of company stock valued at $40,960,735 in the last ninety days. Company insiders own 0.35% of the company’s stock.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.